Advertisement

Les voies de contrôle de l’apoptose

  • Jacques Robert
Part of the Oncologie pratique book series (ONCOLPRAT)

Résumé

L’apoptose constitue une des modalités les plus importantes de mort cellulaire, si importante qu’elle a éclipsé toutes les autres que l’on commence seulement à redécouvrir. L’apoptose est une mort cellulaire programmée, active, mise en oeuvre en réponse à des signaux d’origine intracellulaire (lésions de l’ADN, anomalies de la mitose, stress oxydatif) ou extracellulaires (messages de mort provenant d’autres cellules) et aboutissant à l’activation de protéases capables d’hydrolyser les constituants cellulaires, les caspases. L’apoptose joue une multitude de rôles physiologiques fondamentaux lors de l’embryogenèse et dans l’homéostasie tissulaire: pour ne citer qu’un seul exemple, elle est responsable de l’involution du thymus lors du passage de l’enfance à l’âge adulte. On a fait de l’apoptose la voie de passage obligée de l’action des agents cytotoxiques, même si elle est souvent dans ce cas une conséquence phénotypique secondaire à des mécanismes d’actions ne la concernant qu’indirectement. On l’oppose souvent à la nécrose, alors que d’autres points d’opposition et de comparaison sont également à chercher du côté de la sénescence ou de la mort mitotique.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliographie

  1. Ashkenazi A. (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov; 7: 1001–12.PubMedCrossRefGoogle Scholar
  2. Ashkenazi A. (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer; 2: 420–30.PubMedCrossRefGoogle Scholar
  3. Bao Q, Shi Y. (2007) Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ; 14: 56–65.PubMedCrossRefGoogle Scholar
  4. Chipuk JE, Bouchier-Hayes L, Green DR. (2006) Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Diff; 13: 1396–402.CrossRefGoogle Scholar
  5. Chipuk JE, Green DR. (2008) How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol; 18: 157–64.PubMedCrossRefGoogle Scholar
  6. Cory S, Adams JM. (2002) The BCL2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer; 2: 647–56.PubMedCrossRefGoogle Scholar
  7. Dempsey PW, Doyle SE, He JQ, Cheng G. (2003) The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev; 14: 193–209.PubMedCrossRefGoogle Scholar
  8. Fesik SW. (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer; 5: 876–85.PubMedCrossRefGoogle Scholar
  9. Igney FH, Krammer PH. (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer; 2: 277–88.PubMedCrossRefGoogle Scholar
  10. Johnstone RW, Frew AJ, Smyth MJ. (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer; 8: 782–98.PubMedCrossRefGoogle Scholar
  11. Kang MH, Reynolds CP. (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res; 15: 1126–32.PubMedCrossRefGoogle Scholar
  12. Kruyt FAE. (2008) TRAIL and cancer therapy. Cancer Lett; 263: 14–25.PubMedCrossRefGoogle Scholar
  13. LaCasse EC, Mahoney DJ, Cheung HH et al. (2008) IAP-targeted therapies for cancer. Oncogene; 27: 6252–75.PubMedCrossRefGoogle Scholar
  14. Lessene G, Czabotar PE, Colman P. (2008) BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov; 7: 989–1000.PubMedCrossRefGoogle Scholar
  15. Li J, Yuan J. (2008) Caspases in apoptosis and beyond. Oncogene; 27: 6194–206.PubMedCrossRefGoogle Scholar
  16. Mahalingam D, Szegezdi E, Keane M et al. (2009) TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev; 35: 280–8.PubMedCrossRefGoogle Scholar
  17. Marzo I, Naval J. (2008) Bcl-2 family members as molecular targets in cancer therapy. Biochem Pharmacol; 76: 939–46.PubMedCrossRefGoogle Scholar
  18. Okada H, Mak TW. (2004) Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer; 4: 592–603.PubMedCrossRefGoogle Scholar
  19. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. (2009) Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ; 16: 360–7.PubMedCrossRefGoogle Scholar
  20. Yip KW, Reed JC. (2008) Bcl-2 family proteins and cancer. Oncogene; 27: 6398–406.PubMedCrossRefGoogle Scholar
  21. Youle RJ, Strasser A. (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol; 9: 47–59.PubMedCrossRefGoogle Scholar
  22. Yu JW, Shi Y. (2008) FLIP and the death effector domain family. Oncogene; 27: 6216–27.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2010

Authors and Affiliations

  • Jacques Robert
    • 1
  1. 1.Université Victor Segalen Bordeaux 2Institut BergoniéBordeaux Cedex

Personalised recommendations